
FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases in Lung Cancer
The FDA has granted orphan drug designation to the investigational radiotherapeutic rhenium (186Re) obisbemeda as a potential therapeutic option for leptomeningeal metastases in patients with lung cancer.1 Rhenium (186Re) obisbemeda is formulated to …